Very Solid small company,The Group's financial report for the year ended 30 June 2018 includes:
• Operating revenue from services continued its upward trend reaching $1,176,457, a 27% increase compared tothe previous year.
• Combined income from all sources rose 16% to $2.15 million. Revenue from ordinary activities encapsulatesincome from the Company's analytical services, licensing fees, and grant income including the R&D TaxIncentive.
• Operational expenditure totalled $3.59 million, an increase of 29% in-line with budget, and reflecting anincrease in activity in the commercialisation of PromarkerD and the launch of new analytical services.
• The loss from ordinary activities is $1.44million, which represents a year on year increase of 57%.
• At 30 June 2018 the Company had cash reserves of $2.5 million. On the back of the Company's research anddevelopment focus it anticipates an R&D Tax Incentive cash rebate of $844,123, to be received in the Decemberquarter.
- Forums
- ASX - By Stock
- PIQ
- Ann: Annual Report to shareholders
PIQ
proteomics international laboratories ltd
Add to My Watchlist
0.00%
!
29.0¢

Ann: Annual Report to shareholders, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.42M |
Open | High | Low | Value | Volume |
30.5¢ | 30.5¢ | 28.5¢ | $187.1K | 634.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 81754 | 28.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 81754 | 0.280 |
4 | 147892 | 0.275 |
1 | 25000 | 0.270 |
1 | 10000 | 0.260 |
8 | 102003 | 0.250 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 1000 | 1 |
0.330 | 2000 | 1 |
0.345 | 1260 | 1 |
0.350 | 8000 | 1 |
0.360 | 35000 | 1 |
Last trade - 15.57pm 27/06/2025 (20 minute delay) ? |
Featured News
PIQ (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online